Herbal remedies

New England Journal of Medicine

Volumn 347, Issue 25, 2002, Pages 2046-2056

  De Smet, Peter A G M ^a,b  

^a Scientific Institute Dutch Pharmacists   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOLEVULINIC ACID; AMINOPHENAZONE; AMITRIPTYLINE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE; CORTICOSTEROID; CYCLOSPORIN; DIGITALIS GLYCOSIDE; DIGOXIN; FENFLURAMINE; HERBACEOUS AGENT; INDINAVIR; INDOMETACIN; MIDAZOLAM; NEFAZODONE; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHENPROCOUMON; PHENYLBUTAZONE; ROFECOXIB; SERTRALINE; SILDENAFIL; SIMVASTATIN; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

BLEEDING; CARCINOGENICITY; CARDIOTOXICITY; CLINICAL TRIAL; COMA; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEMENTIA; DEPRESSION; DIAPHORESIS; DIARRHEA; DISORIENTATION; DRUG CONTAMINATION; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EJACULATION DISORDER; EMBRYOTOXICITY; FATIGUE; FETOTOXICITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GINKGO BILOBA; GOOD MANUFACTURING PRACTICE; HEADACHE; HEART FAILURE; HEART PALPITATION; HERBAL MEDICINE; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOKALEMIA; ISCHEMIA; LETHARGY; LIVER TOXICITY; MANIA; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; SEIZURE; SEROTONIN SYNDROME; SHOCK; SKIN MANIFESTATION; THORAX PAIN; TREATMENT INDICATION; UROGENITAL TRACT TUMOR; VERTIGO; XEROSTOMIA;

COMPLEMENTARY THERAPIES; CONTROLLED CLINICAL TRIALS; CRATAEGUS; DEMENTIA; DEPRESSION; DRUG CONTAMINATION; GINKGO BILOBA; HEART FAILURE, CONGESTIVE; HUMANS; HYPERICUM; INTERMITTENT CLAUDICATION; MALE; MEDICINE, HERBAL; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; TREATMENT OUTCOME; UNITED STATES;

EID: 0037137560     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra020398     Document Type: Review

References (127)

1. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998;280:1569-75.
2. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286:208-16.
3. Blumenthal M, ed. The Complete German Commission E Monographs - Therapeutic Guide to Herbal Medicines. Austin, Tex.: American Botanical Council, 1998.
4. Licensing of Medicines: Policy on Herbal Medicines. Herbal Safety News. London: Medicines Control Agency, 2002. (Accessed November 22, 2002, at http://www.mca.gov.uk/ourwork/licensingmeds/herbalmeds/ herbalsafety.htm).
5. De Smet PAGM. Health risks of herbal remedies. Drug Saf 1995;13:81-93.
6. Idem. Toxicological outlook on the quality assurance of herbal remedies. In: De Smet PAGM, Keller K, Hänsel R, Chandler RF, eds. Adverse effects of herbal drugs. Vol. 1. Berlin, Germany: Springer-Verlag, 1992: 1-72.
7. Idem. The safety of herbal products. In: Jonas WB, Levin JS, eds. Essentials of complementary and alternative medicine. Philadelphia: Lippincott Williams & Wilkins, 1999:108-47.
8. Nortier JL, Martinez M-CM, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686-92.
9. Lord GM, Tagore R, Cook T, Gower P, Pusey CD. Nephropathy caused by Chinese herbs in the UK. Lancet 1999;354:481-2.
10. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001;358:1515-6.
11. Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm 2000; 57:963-9.
12. Miwa H, Iijima M, Tanaka S, Mizuno Y. Generalized convulsions after consuming a large amount of gingko nuts. Epilepsia 2001;42:280-1.
13. Kajiyama Y, Fujii K, Takeuchi H, Manabe Y. Ginkgo seed poisoning. Pediatrics 2002;109:325-7.
14. Gregory PJ. Seizure associated with Ginkgo biloba? Ann Intern Med 2001;134:344.
15. Granger AS. Ginkgo biloba precipitating epileptic seizures. Age Ageing 2001;30:523-5.
16. Arenz A, Klein M, Fiehe K, et al. Occurrence of neurotoxic 4′-O-methylpyridoxine in Ginkgo biloba leaves, ginkgo medications and Japanese ginkgo food. Planta Med 1996;62:548-51.
17. Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 1999;117:1234-7.
18. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002;287:337-44.
19. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial. Eur J Cancer 2001;37:23-31.
20. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. 1. Ethical and scientific issues. Ann Intern Med 2000;133:455-63.
21. Ernst E, Pittler MH. Alternative therapy bias. Nature 1997;385:480.
22. Pittler MH, Abbot NC, Harkness EF, Ernst E. Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiol 2000;53:485-9.
23. Ernst E, Pittler MH. Ginkgo biloba for dementia: A systematic review of double-blind, placebo-controlled trials. Clin Drug Invest 1999;17:301-8.
24. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: A meta-analysis of randomized trials. Am J Med 2000; 108:276-81.
25. Moher D, Pharn B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: A meta-analysis of randomised trials. Drugs 2000;59:1057-70.
26. Ernst E, Stevinson C. Ginkgo biloba for tinnitus: A review. Clin Otolaryngol 1999;24:164-7.
27. Weihmayr T, Ernst E. Die therapeutische Wirksamkeit von Crataegus. Fortschr Med 1996;114:27-9.
28. Wilt T, Ishani A, Stark G, MacDonald R, Mulrow C, Lau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2001; 2:CD001423
29. Saw Palmetto. Rockville, Md.: Pharmacopeial Convention, 2002. (Accessed November 22, 2002, at http://www.usp.org.).
30. Gaster B, Holroyd J. St John's Wort for depression: A systematic review. Arch Intern Med 2000;160:152-6.
31. Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 2000;132:743-56.
32. Linde K, Mulrow CD. St John's Wort for depression. Cochrane Database Syst Rev 2000;2:CD000448.
33. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: A comprehensive clinical review. Int Clin Psychopharmacol 2001;16:239-52.
34. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng: A systematic review of randomised clinical trials. Eur J Clin Pharmacol 1999;55:567-75.
35. Kitts D, Hu C. Efficacy and safety of ginseng. Public Health Nutr 2000;3:473-85.
36. Giles JT, Palat CT III, Chien SH, Chang ZG, Kennedy DT. Evaluation of echinacea for treatment of the common cold. Pharmacotherapy 2000;20:690-7.
37. Melchart D, Linde K, Fischer P, Kaesmayr J. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2000;2: CD000530.
38. Budeiri D, Li Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome? Control Clin Trials 1996;17: 60-8.
39. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): An update of a systematic review. Public Health Nutr 2000;3:509-14.
40. Ackermann RT, Mulrow CD, Ramirez G, Gardner CD, Morbidoni L, Lawrence VA. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 2001;161:813-24.
41. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: A systematic review of randomized clinical trials. Br J Anaesth 2000;84:367-71.
42. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2002;2:CD003383.
43. Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001;322:139. [Erratum, BMJ 2001;322:1097.]
44. Provisional MCA Assessment of the Relative Strength of Evidence Relating to the Individual Case Reports of Kava ADRs. London: European Herbal Practitioners Association, 2002. (Accessed November 22, 2002, at http: //www.users.globalnet.co.uk/∼ehpa/mcakavacases0202.htm.)
45. Mulrow C, Lawrence V, Jacobs B, et al. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evidence Report/Technology Assessment. No. 21. Rockville, Md.: Agency for Healthcare Research and Quality, October 2000. (AHRQ publication no. 01-E025.) (Accessed November 22, 2002, at http://www.ahcpr.gov/clinic/epcsums/milktsum. htm.)
46. Stevinson C, Ernst E. Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Med 2000;1:91-9.
47. Echinacea for prevention and treatment of upper respiratory infections. Med Lett Drugs Ther 2002;44:29-30.
48. Drieu K, DeFeudis FV. In vivo studies of the pharmacological and biochemical activities of Ginkgo biloba extract (EGb 761) and its constituents. In: Van Beek TA, ed. Ginkgo Biloba. Amsterdam: Harwood Academic, 2000:303-29.
49. Braquet P, Hosford D. Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents. J Ethnopharmacol 1991;32: 135-9.
50. Oyama Y, Fuchs PA, Katayama N, Noda K. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res 1994;635:125-9.
51. Braquet P. Cedemin, a Ginkgo biloba extract, should not be considered as a PAF antagonist. Am J Gastroenterol 1993;88:2138.
52. Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47-56.
53. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-32.
54. Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord 2000;11:230-7.
55. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183-94.
56. Sherwin BB. Mild cognitive impairment: Potential pharmacological treatment options. J Am Geriatr Soc 2000;48:431-41.
57. Peters H, Kieser M, Holscher U. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication - A placebo-controlled, double-blind multicenter trial. Vasa 1998;27:106-10.
58. De Backer TL, Vander Stichele RH, Warie HH, Bogaert MG. Oral vasoactive medication in intermittent claudication: Utile or futile? Eur J Clin Pharmacol 2000;56:199-206.
59. Drew S, Davies E. Effectiveness of Ginkgo biloba in treating tinnitus: Double blind, placebo controlled trial. BMJ 2001;322:73.
60. Burkard G, Lehrl S. Verhältnis von Demenzen vom Multiinfarkt- und vom Alzheimertyp in ärztlichen Praxen: Diagnostische und therapeutische Konsequenzen am Beispiel eines Ginkgo-biloba Präparates. MMW Munch Med Wochenschr 1991;133:Suppl 1:38-43.
61. Ginkgo-biloba-haltiger trocknextrakt zur infusion. Pharm Ztg 1994; 139:986-87.
62. Mossabeb R, Kraft D, Valenta R. Evaluation of the allergenic potential of Ginkgo biloba extracts. Wien Klin Wochenschr 2001;113:580-7.
63. Gilbert GJ. Ginkgo biloba. Neurology 1997;48:1137.
64. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998;352:36.
65. Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage - Can Ginkgo biloba be implicated? Postgrad Med J 2001;77:112-3.
66. Davydov L, Stirling AL. Stevens-Johnson syndrome with Ginkgo biloba. J Herbal Pharmacother 2001;1:65-9.
67. Galluzzi S, Zanetti O, Binetti G, Trabucchi M, Frisoni GB. Coma in a patient with Alzheimer's disease taking low dose trazodone and gingko biloba. J Neurol Neurosurg Psychiatry 2000;68:679-80.
68. Schulz V, Hänsel R, Tyler VE. Rational Phytotherapy: A Physician's Guide to Herbal Medicine. 4th Ed. Berlin, Germany: Springer-Verlag, 2001.
69. Joseph G, Zhao Y, Klaus W. Pharmakologische wirkprofil von crataegus-extrakt im vergleich zu epinephrin, amrinon, milrinon und digoxin am isoliert perfundierten meerschweinchenherzen. Arzneimittelforschung 1995;45:1261-65.
70. Ammon HPT, Händel M. Crataegus, toxikologie und pharmakologie. II. Pharmakodynamik. Planta Med 1981;43:209-39.
71. Chatterjee SS, Koch E, Jaggy H, Krzeminski T. In-vitro- und in-vivo-untersuchungen zur kardioprotektiven wirkung von ohgomeren procyanidinen in einem crataegus-extrakt aus blättern mit blüten. Arzneimittelforschung 1997;47:821-5.
72. Rothfuss MA, Pascht U, Kissling G. Effect of long-term application of Crataegus oxyacantha on ischemia and reperfusion induced arthythmias in rats. Arzneimittelforschung 2001;51:24-8.
73. Schwinger RH, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 2000;35:700-7y.
74. Lacaille-Dubois MA, Franck U, Wagner H. Search for potential angiotensin converting enzyme (ACE)-inhibitors from plants. Phytomedicine 2001;8:47-52.
75. Gundling K, Ernest E. Complementary and alternative medicine in cardiovascular disease: What is the evidence it works? West J Med 1999; 171:191-4.
76. Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002;143:910-5.
77. Felker GM, O'Connor CM. Inotropic therapy for heart failure: An evidence-based approach. Am Heart J 2001;142:393-401.
78. Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M. Survival and prognosis: Investigation of crataegus extract WS 1442 in congestive heart failure (SPICE) - Rationale, study design and study protocol. Eur J Heart Fail 2000;2:431-7.
79. Schmidt U, Albrecht M, Podzuweit H, Ploch M, Maisenbacher J. Hochdosierte crataegus-therapie bei herzinsuffizienten patienten NYHA-stadium I und II. Z Phytother 1998;19:22-30.
80. Tauchert M, Gildor A, Lipinski J. Einsatz des hochdosierten crataegusextraktes WS 1442 in der therapie der herzinsuffizienz stadium NYHA II. Herz 1999;24:465-74. [Erratum, Herz 1999;24:586.]
81. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 2000;163:1408-12.
82. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37:77-83.
83. Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-14.
84. Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon) in benign prostatic hyperplasia. Prostate 2000;45:259-66.
85. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate 1996;29: 231-40.
86. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58:960-4.
87. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an a-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur Urol 2002;41:497-507.
88. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: A case report and review of literature. J Intern Med 2001;250:167-9.
89. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997;30:Suppl 2:129-34.
90. Gobbi M, Moia M, Pirona L, Morizzoni P, Mennini T. In vitro binding studies with two Hypericum perforatum extracts - Hyperforin, hypericin and biapigenin - On 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 2001;34:Suppl 1:S45-S48.
91. Fornal CA, Metzler CW, Mirescu C, Stein SK, Jacobs BL. Effects of standardized extracts of St. John's Wort on the single-unit activity of serotonergic dorsal Raphe neurons in awake cats: Comparisons with fluoxetine and sertraline. Neuropsychopharmacology 2001;25:858-70.
92. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998;63:499-510.
93. Bhattacharya SK, Chakrabarti A, Chatterjee SS. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. Pharmacopsychiatry 1998;31:Suppl 1:22-9.
94. Flausino OA Jr, Zangrossi H Jr, Salgado JV, Viana MB. Effects of acute and chronic treatment with Hypericum perforatum L. (LI 160) on different anxiety-related responses in rats. Pharmacol Biochem Behav 2002;71: 251-7.
95. Davidson JR, Connor KM. St. John's Wort in generalized anxiety disorder: Three case reports. J Clin Psychopharmacol 2001;21:635-6.
96. De Smet PAGM, Nolen WA. St John's Wort as an antidepressant. BMJ 1996;313:241-2.
97. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's Wort in major depression: A randomized controlled trial. JAMA 2001;285: 1978-86.
98. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. Ann Intern Med 2000;132:738-42.
99. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: A randomized controlled trial. JAMA 2002;287:1807-14.
100. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomised multicentre study of treatment for eight weeks. BMJ 1999;319:1534-8. [Erratum, BMJ 2000;320:361.]
101. Wheatley D. LI 160, an extract of St. John's Wort, versus amitriptyline in mildly to moderately depressed outpatients - A controlled 6-week clinical trial. Pharmacopsychiatry 1997;30:Suppl 2:77-80.
102. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's Wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997;30:Suppl 2:81-5.
103. Woelk H. Comparison of St John's Wort and imipramine for treating depression: Randomised controlled trial. BMJ 2000;321:536-9.
104. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's Wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999;49:289-96.
105. Schrader E. Equivalence of St John's Wort extract (Ze 117) and fluoxetine: A randomized controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000;15:61-8.
106. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin Ther 2000;22:411-9.
107. Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 2002;19:43-52.
108. van Gurp G, Meterissian GB, Haiek LN, McCusker J, Bellavance E St John's Wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 2002;48:905-12.
109. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's Wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998;54:589-94.
110. Schempp CM, Muller K, Winghofer B, Schulte-Monting J, Simon JC. Single-dose and steady-state administration of Hypericum perforatum extract (St John's Wort) does not influence skin sensitivity to UV radiation, visible light, and solar-simulated radiation. Arch Dermatol 2001;137:512-3. [Erratum, Arch Dermatol 2001;137:1380.]
111. Golsch S, Vocks E, Rakoski J, Brockow K, Ring J. Reversible Erhöhung der photosensitivität im UV-B-Bereich dutch Johanniskrautextrakt-Präparate. Hautarzt 1997;48:249-52.
112. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John's Wort. Lancet 1998;352:1121-2.
113. Lane-Brown MM. Photosensitivity associated with herbal preparations of St John's Wort (Hypericum perforatum). Med J Aust 2000;172: 302.
114. Moses EL, Mallinger AG. St. John's Wort: Three cases of possible mania induction. J Clin Psychopharmacol 2000;20:115-7.
115. Lal S, Iskandar H. St. John's Wort and schizophrenia. CMAJ 2000; 163:262-3.
116. Brown TM. Acute St. John's Wort toxicity. Am J Emerg Med 2000; 18:231-2.
117. Parker V, Wong AH, Boon HS, Seeman MV. Adverse reactions to St John's Wort. Can J Psychiatry 2001;46:77-9.
118. Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's Wort. Am J Med 2002;112:507-8.
119. Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: Long-term use of St. John's Wort. J Clin Anesth 2000;12:498-9.
120. Crowe S, McKeating K. Delayed emergence and St. John's wort. Anesthesiology 2002;96:1025-7.
121. Ferko N, Levine MA. Evaluation of the association between St. John's wort and elevated thyroid-stimulating hormone. Pharmacotherapy 2001;21:1574-8.
122. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000;68:605-12.
123. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's Wort: Effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67: 451-7.
124. Dürr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
125. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26.
126. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St. John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000;166:R11-R16.
127. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001;134:1601-8.